A new computational tool infers changes occurring at the ends of the chromosomes housing our DNA. It does so by detecting structural alterations in ...

Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...

Researchers discovered that a small region of the PRC2 protein complex acts as a functional switch controlling gene silencing. Removing this domain stopped cancer cell growth, highlighting a potential ...

Cancers emerge from many different paths. One path begins early, in embryonic development, when a protein complex called PRC2 ...

Phase 1 dose-escalation advancing as planned, targeting SMARCA4 (BRG1)-mutant cancers with a focus on non-small cell lung cancer (NSCLC) Selective CBP degrader program with potential in ER+ breast can ...

Cancer biology increasingly recognizes that cancer stem cells (CSCs) represent a critical subpopulation within tumors, marked by their self-renewal, ...

Reviewing the role, regulatory mechanisms and therapeutic potential of METTL16 in cancer Cancer remains a leading cause of mortality, with its onset ...

With clinical data beginning to emerge, big pharma is signaling its belief that in vivo CAR generation is the next immunotherapy breakthrough.

Cas9, Transcription Activator-Like Effector Nucleases (TALENs), and Zinc-Finger nucleases (ZFNs) have demonstrated great utility, primarily for genetic knock-out applications, none have been adopted ...

Researchers have pinpointed a key regulator behind how GLP-1 drugs promote viability and stress resistance in pancreatic beta cells.

Our genetic code is shaped by our surroundings, diet, where we live, our activities, and many other factors. When these influences do not alter our ...

Removing polyamines or eIF5A2 from the cells reduced the growth of cancer cells significantly, while returning spermidine restored the cancer's expansion. That's strong evidence that spermidine may ...